Cancer Research Institute’s first comprehensive, data-driven look at the trajectory of cancer immunotherapy traces the evolution of the field from 2011 through the end of 2024. The goal of the report is to equip the field with a rigorous synthesis of regulatory trends, mechanistic advances, and clinical utilization, in order to track how the field is progressing and where it is heading.
To read the full report, click here.
Speakers
Alicia Zhou, PhD
CEO
Cancer Research Institute
Samik Upadhaya, PhD
Director of Scientific Affairs
Cancer Research Institute
Cynthia Neben, PhD
Director of Strategic Programs
Cancer Research Institute
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.